연구
교육
솔루션
로그인
KR
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
TR - Turkish
JA - Japanese
Veerendra Munugalavadla has not added Biography.
If you are Veerendra Munugalavadla and would like to personalize this page please email our Author Liaison for assistance.
Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.
Cancer discovery 03, 2020 | Pubmed ID: 31915195
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Lancet (London, England) 04, 2020 | Pubmed ID: 32305093
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.
Cancer Oct, 2020 | Pubmed ID: 32757302
Acerta Pharma, AstraZeneca Group
Paola Marco-Casanova1,
Natalia Lukashchuk1,
Benedetta Lombardi1,
Veerendra Munugalavadla2,
Melanie M. Frigault3,
Elizabeth A. Harrington1,
J. Carl Barrett3,
Andrew J. Pierce1
1Translational Medicine, R&D Oncology, AstraZeneca,
2, Acerta Pharma, AstraZeneca Group,
3Translational Medicine, R&D Oncology, AstraZeneca
개인 정보 보호
이용 약관
정책
연락처
사서에게 추천하기
JoVE 뉴스레터
JoVE Journal
연구 방법 컬렉션
JoVE Encyclopedia of Experiments
아카이브
JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
교수 리소스 센터
저자
사서
액세스
JoVE 소개
Copyright © 2024 MyJoVE Corporation. 판권 소유
